A first-in-class multimodal immunotherapy for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors

被引：0
|
作者：
Diers, Anne R.
Guo, Qiuchen
Christie, John D.
Krisky, David
Gaspal, Fabrina M.
Richardson, Erin
Smith, Charlotte G.
Withers, David R.
Croft, Adam P.
Tak, Paul P.
Barone, Francesca
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB263
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors
    van Rijthoven, Mart
    Obahor, Simon
    Pagliarulo, Fabio
    van den Broek, Maries
    Schraml, Peter
    Moch, Holger
    van der Laak, Jeroen
    Ciompi, Francesco
    Silina, Karina
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [22] Multi-resolution deep learning characterizes tertiary lymphoid structures and their prognostic relevance in solid tumors
    Mart van Rijthoven
    Simon Obahor
    Fabio Pagliarulo
    Maries van den Broek
    Peter Schraml
    Holger Moch
    Jeroen van der Laak
    Francesco Ciompi
    Karina Silina
    Communications Medicine, 4
  • [23] First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas.
    Rixe, Olivier
    Morris, John Charles
    Puduvalli, Vinay K.
    Villano, John L.
    Wise-Draper, Trisha Michel
    Muller, Carolyn
    Johnson, Angela N.
    Wesolowski, Robert
    Qi, Xiaoyang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] SINGLE INSTITUTION PHASE I TRIAL OF THE NOVEL COMPOUND FIRST-IN-CLASS PDM08 IN REFRACTORY SOLID TUMORS (NCT01380249)
    Barriuso, J.
    Soria, I.
    Moreno, V.
    Coronado, M.
    Galicia, I.
    Figueredo, M. A.
    Frias, J.
    Feliu, J.
    Carcas, A.
    Subiza, J. L.
    ANNALS OF ONCOLOGY, 2012, 23 : 165 - 165
  • [25] A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
    Middleton, Mark
    Evans, Jeff
    Steven, Neil
    Corrie, Pippa
    Mulatero, Clive
    Sznol, Mario
    Shingler, William H.
    Smethurst, Dominic
    Hassan, Namir
    McGrath, Yvonne
    Jakobsen, Bent
    CANCER RESEARCH, 2014, 74 (19)
  • [26] A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
    Lee, C. H.
    Cho, M.
    Kim, J.
    Lee, J.
    Kim, D.
    Park, M.
    Kim, Y.
    Hang, J.
    Park, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [27] Phase I trial in advanced refractory solid tumors of the new drug first-in-class PDM08.
    Barriuso, Jorge
    Moreno, Victor
    Coronado, Monica
    Galicia, Ignacio
    Soria, Irene
    de Castro, Javier
    Belda-Iniesta, Cristobal
    Martinez Marin, Virginia
    Custodio, Ana
    Redondo, Andres
    Lamarca, Angela
    Hindi, Nadia
    Luis Subiza, Jose
    Frias, Jesus
    Feliu, Jaime
    Carcas, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
    Advani, Ranjana H.
    Hurwitz, Herbert I.
    Gordon, Michael S.
    Ebbinghaus, Scot W.
    Mendelson, David S.
    Wakelee, Heather A.
    Hoch, Ute
    Silverman, Jeffrey A.
    Havrilla, Nancy A.
    Berman, Craig J.
    Fox, Judith A.
    Allen, Roberta S.
    Adelman, Daniel C.
    CLINICAL CANCER RESEARCH, 2010, 16 (07) : 2167 - 2175
  • [29] LABP-66: A Novel NLRX1-Targeting First-in-Class Therapeutic for Multiple Sclerosis
    Leber, A.
    Hontecillas, R.
    Tubau-Juni, N.
    Fitch, S. N.
    Bassaganya-Riera, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 96 - 96
  • [30] STROMAL CELLS IN TERTIARY LYMPHOID STRUCTURES: A NOVEL PATHOGENIC PARADIGM AND THERAPEUTIC TARGET IN SJOGREN'S SYNDROME
    Nayar, Saba
    Campos, Joana
    Caamano, Jorge
    Fisher, Benjamin
    Bowman, Simon
    Luther, Sanjiv
    Coles, Mark
    Buckley, Christopher
    Barone, Francesca
    RHEUMATOLOGY, 2017, 56 : 34 - 34
12345